🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Advanced Solid Tumors
Clinical trial register · Spain

Advanced Solid Tumors Trials in Spain, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Spain and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5885 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:52 UTC
5885
Studies in scope
all four open statuses
3103
Recruiting now
open to new participants
1139
Lead sponsors
across recruiting studies
Top sites
Madrid 35 Barcelona 32 Pamplona 9 Valencia 9 Málaga 6
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Merck Sharp & Dohme LLC3 AbbVie3 Bayer3 Bristol-Myers Squibb2 Vividion Therapeutics, Inc.2
Site location
Madrid35 Barcelona32 Pamplona9 Valencia9 Málaga6
All 20 locations
Target enrolment
to

Advanced Solid Tumors trials in Spain

35 of 5885 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Spain
Start
Recruiting
Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participants With Advanced Solid Tumors
NCT07387068Advanced Solid Tumors
Genmab
Phase 1
121
Logroño, Pozuelo de Alarcón, Pamplona, Barcelona, Madrid
2026-04-07
Recruiting
A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors
NCT07524348Advanced Solid Tumors
Samsung Bioepis Co., Ltd.
Phase 1
149
Barcelona, Madrid
2026-03-23
Recruiting
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
NCT07360314Advanced Solid Tumors
EMD Serono Research & Development Institute, Inc.
Phase 1
138
Barcelona, Madrid
2026-02-13
Recruiting
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
NCT07262619Advanced Solid Tumors, MSI-H or dMMR Advanced Solid Tumors, MSI-H/dMMR Gastric Cancer, MSI-H/dMMR Colorectal Cancer
DrugsKeytruda·Pembrolizumab
Eikon Therapeutics
Phase 1/2
160
Barcelona, Logroño, Madrid, Zaragoza
2026-01-20
Recruiting
A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors
NCT07266428Advanced Solid Tumors
Ottimo Pharma Limited
Phase 1/2
170
Madrid
2025-12-17
Recruiting
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
NCT07161414Advanced Solid Tumors
DrugsRecombinant Human Hyaluronidase·Rilvegostomig
AstraZeneca
Phase 1
40
Barcelona, Madrid
2025-11-25
Recruiting
A Study to Test a New Immunotherapy, ABX-001, Alone and in Combination With the Marketed Drug, Pembrolizumab, for the Treatment of Tumors Previously Treated With Other Therapies
NCT07231458Advanced Solid Tumors
DrugPembrolizumab
Abalos Therapeutics GmbH
Phase 1
27
Barcelona, Madrid
2025-10-14
Active, closed
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
NCT07038369Advanced Solid Tumors, Breast Cancer, Breast Carcinoma, Breast Neoplasms
DrugATV-1601
Atavistik Bio, Inc
Phase 1
134
Madrid
2025-07-29
Recruiting
Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors
NCT06795412Advanced Solid Tumors
DrugsPYX-201·Keytruda·Pembrolizumab
Pyxis Oncology, Inc
Phase 1/2
220
Barcelona, Madrid, Valencia
2025-04-15
Recruiting
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
NCT06818643Advanced Solid Tumors, Malignant Neoplasm
DrugMK-3120
Merck Sharp & Dohme LLC
Phase 1/2
270
L'Hospitalet de Llobregat, Barcelona, Madrid, Málaga
2025-03-25
Recruiting
A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors
NCT06697197Advanced Solid Tumors
DrugsNivolumab and rHuPH20·Bevacizumab
Bristol-Myers Squibb
Phase 1/2
413
Barcelona, Pamplona, Madrid
2025-02-17
Recruiting
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
NCT06760819Advanced Solid Tumors, HER2 Mutation
Bayer
Phase 2
111
L'Hospitalet de Llobregat, Barcelona, Madrid
2025-02-13
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Tubulis GmbH
Phase 1/2
250
Barcelona, Madrid
2024-12-13
Active, closed
A Study of ZW191 in Participants With Solid Tumors
NCT06555744Advanced Solid Tumors
Zymeworks BC Inc.
Phase 1
145
Barcelona, Córdoba, Madrid, Valencia
2024-10-30
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
DrugsAtirmociclib·Tucatinib·Ribociclib·Trastuzumab
OnKure, Inc.
Phase 1
200
Barcelona, Madrid
2024-02-26
Recruiting
A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors
NCT06004245Advanced Solid Tumors, Colorectal Cancer
DrugsVVD-133214·Bevacizumab·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 1
280
Barcelona, Madrid, Pamplona, Valencia
2024-01-25
Recruiting
A Study of JNJ-87890387 for Advanced Solid Tumors
NCT06178614Neoplasms, Advanced Solid Tumors
Janssen Research & Development, LLC
Phase 1
200
Barcelona, Madrid
2023-12-14
Recruiting
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
NCT05954312Advanced Solid Tumors
DrugsDocetaxel·Paclitaxel·Pembrolizumab
Vividion Therapeutics, Inc.
Phase 1
290
Barcelona, Madrid, Pamplona, Valencia
2023-07-28
Recruiting
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
NCT05836324Solid Tumors, Advanced Solid Tumors, Metastatic Solid Tumors
DrugsINCA33890·ADG126·Folfiri·Folfox
Incyte Corporation
Phase 1
570
Barcelona, Madrid
2023-07-24
Active, closed
Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)
NCT05853367Metastatic Solid Tumors, Advanced Solid Tumors
DrugsMK-1084·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 1
95
L'Hospitalet de Llobregat, Madrid, Barcelona, Seville
2023-07-06
Active, closed
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT05888831Advanced Solid Tumors
DrugNivolumab
Bristol-Myers Squibb
Phase 1/2
100
Málaga, Badalona, Pamplona, Madrid
2023-06-06
Recruiting
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT05592626Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
DrugSTAR0602
Marengo Therapeutics, Inc.
Phase 1/2
366
Barcelona, Madrid, Valencia
2023-01-04
Active, closed
Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors
NCT05599984Advanced Solid Tumors
DrugsABBV-706·Budigalimab·Cisplatin·Carboplatin
AbbVie
Phase 1
288
Barcelona, Madrid, Seville, Valencia
2022-12-05
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY2965501 is, Find the Best Dose (Single Drug & Combination), How it Affects the Body, What Maximum Amount Can be Given, How it Moves Into, Through and Out of the Body, How it Acts on Different Tumors in Participants With Advanced Solid Tumors
NCT05614102Advanced Solid Tumors
DrugPembrolizumab
Bayer
Phase 1
284
Pamplona, Barcelona, Madrid
2022-11-04
Active, closed
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT05537740Advanced Solid Tumors
DrugPembrolizumab
Bayer
Phase 1
129
Pamplona, Barcelona, Madrid
2022-10-11
Recruiting
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
NCT05533697Advanced Solid Tumors
DrugsIpilimumab·Nivolumab·Pembrolizumab
ModernaTX, Inc.
Phase 1/2
361
Logroño, Barcelona, Madrid, Málaga
2022-09-01
Recruiting
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
NCT05067283Advanced Solid Tumors
DrugsCalderasib·Leucovorin·Adrucil·Cetuximab
Merck Sharp & Dohme LLC
Phase 1
830
Madrid, Barcelona
2021-12-17
Active, closed
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT05029882Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer
DrugsTelisotuzumab Adizutecan·Trifluridine/Tipiracil·Bevacizumab
AbbVie
Phase 1
520
Santiago de Compostela, Badalona, Alcorcón, Pamplona, Barcelona, Jaén, Madrid, Seville
2021-10-13
Active, closed
A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers
NCT04626635Advanced Solid Tumors
DrugsMarlotamig·Trifluridine/Tipiracil·Cemiplimab·Bevacizumab
Regeneron Pharmaceuticals
Phase 1/2
548
Sant Cugat del Vallès, Pozuelo de Alarcón, Barcelona, Madrid, Valencia
2020-12-21
Active, closed
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Solid Tumors
NCT05593094Advanced Solid Tumors, HER2-positive Breast Cancer
DrugZN-A-1041
Hoffmann-La Roche
Phase 1/2
210
Argentona, Santiago de Compostela, A Gudiña, Las Cabezas de San Juan, Barcelona, Jaén, Madrid, Seville
2020-09-03
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT04449874Non-Small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumors
DrugsDivarasib·Erlotinib·Inavolisib·Cetuximab
Genentech, Inc.
Phase 1
498
Barcelona, Madrid, Málaga, Seville, Valencia
2020-07-29
Active, closed
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
NCT04185883Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DrugsBI 1701963·Bevacizumab-awwb·TNO155·Mvasi
Amgen
Phase 1
610
Barcelona, L'Hospitalet de Llobregat, Majadahonda, Madrid
2019-12-17
Active, closed
Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments
NCT04058756Advanced Solid Tumors
DrugSpartalizumab
Novartis Pharmaceuticals
Phase 1
120
L'Hospitalet de Llobregat, Barcelona, Madrid, Valencia
2019-10-30
Active, closed
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors
NCT03893955Cancer, Advanced Solid Tumors, Triple-Negative Breast Cancer (TNBC), Non-small-cell-lung-cancer (NSCLC)
DrugsABBV-927·Budigalimab·Nab-paclitaxel·Carboplatin
AbbVie
Phase 1
150
Barcelona, Madrid, Málaga
2019-05-21
Active, closed
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
NCT02671435Advanced Solid Tumors
DrugsMonalizumab·MFOLFOX6·Cetuximab·Durvalumab
MedImmune LLC
Phase 1/2
383
Barcelona, Madrid, Málaga, Pamplona, Seville
2016-02-22
Rows per page Showing 1–35 of 35
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Spanish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-spain/condition/advanced-solid-tumors

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Spain and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,885 studies in total at the last sync on 26 Sep 2026, 19:52 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 35 of those studies listing the condition Advanced Solid Tumors.

How many Advanced Solid Tumors trials are recruiting in Spain?

19 of the 35 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:52 UTC sync. A further 0 have not yet opened recruitment, 16 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Advanced Solid Tumors), 35 studies
PhaseStudiesRecruitingShare
Phase 1221062.9%
Phase 1/212834.3%
Phase 2112.9%

Most active sponsors

Lead sponsors with the most studies (Advanced Solid Tumors)
Lead sponsorStudiesRecruiting
AbbVie30
Bayer31
Merck Sharp & Dohme LLC32
Bristol-Myers Squibb21
Vividion Therapeutics, Inc.22
Abalos Therapeutics GmbH11
Amgen10
AstraZeneca11
Atavistik Bio, Inc10
Eikon Therapeutics11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.